Skip to main content
. Author manuscript; available in PMC: 2021 Apr 5.
Published in final edited form as: Biochem Pharmacol. 2020 Oct 2;182:114259. doi: 10.1016/j.bcp.2020.114259

Fig. 3.

Fig. 3.

Apigenin reduces the viability of human TNBC PDX organoids at concentrations achievable in vivo. (A) Schematic representation of organoid formation from human TNBC PDX HCI001 derived from patient-derived xenografts. Organoids were treated with 1, 5, 10, 25, 50 μM apigenin or vehicle DMSO (indicated as 0) for 5 days. (B) Growth represented as Δ diameter between day 5 and day 0 of organoids treated as shown in (A). (C) Percentage of cell viability relative to DMSO in organoids treated as shown in (A). Data represent mean ± SEM, N = 4; each biological repeat (N) comprised of 10–15 organoids. *p < 0.05, **p < 0.001, compared to DMSO vehicle control.